Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Drug Approval | 59 | 2022 | 742 | 9.060 |
Why?
|
Drug Industry | 69 | 2022 | 746 | 8.500 |
Why?
|
United States Food and Drug Administration | 82 | 2022 | 1584 | 8.060 |
Why?
|
Drug Costs | 50 | 2022 | 1105 | 4.680 |
Why?
|
Prescription Drugs | 29 | 2021 | 595 | 4.650 |
Why?
|
Drugs, Generic | 36 | 2022 | 421 | 4.530 |
Why?
|
Drug Prescriptions | 64 | 2019 | 1637 | 4.010 |
Why?
|
Government Regulation | 20 | 2021 | 522 | 3.950 |
Why?
|
Marketing | 19 | 2017 | 212 | 3.920 |
Why?
|
Legislation, Drug | 16 | 2022 | 206 | 3.120 |
Why?
|
Drug Evaluation | 10 | 2020 | 647 | 2.390 |
Why?
|
Off-Label Use | 9 | 2020 | 169 | 2.350 |
Why?
|
Drug Discovery | 12 | 2020 | 1058 | 2.330 |
Why?
|
Drug Labeling | 19 | 2015 | 233 | 2.200 |
Why?
|
Product Surveillance, Postmarketing | 17 | 2022 | 430 | 2.180 |
Why?
|
United States | 254 | 2023 | 69872 | 2.030 |
Why?
|
Drug Utilization | 56 | 2016 | 1183 | 1.990 |
Why?
|
Patents as Topic | 15 | 2022 | 103 | 1.950 |
Why?
|
Antihypertensive Agents | 22 | 2019 | 2047 | 1.940 |
Why?
|
Pharmacoepidemiology | 15 | 2013 | 323 | 1.920 |
Why?
|
Insurance, Pharmaceutical Services | 20 | 2021 | 336 | 1.830 |
Why?
|
Medicaid | 45 | 2023 | 2737 | 1.810 |
Why?
|
Orphan Drug Production | 5 | 2021 | 50 | 1.730 |
Why?
|
Drug Therapy | 19 | 2012 | 497 | 1.720 |
Why?
|
Device Approval | 7 | 2021 | 163 | 1.660 |
Why?
|
Financing, Government | 7 | 2021 | 468 | 1.660 |
Why?
|
Drug Utilization Review | 18 | 2016 | 245 | 1.570 |
Why?
|
Drug and Narcotic Control | 7 | 2021 | 146 | 1.560 |
Why?
|
Cyclooxygenase Inhibitors | 11 | 2007 | 371 | 1.540 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 36 | 2018 | 3255 | 1.510 |
Why?
|
Patient Compliance | 31 | 2011 | 2684 | 1.500 |
Why?
|
Pharmaceutical Preparations | 18 | 2023 | 1070 | 1.500 |
Why?
|
New Jersey | 39 | 2015 | 290 | 1.490 |
Why?
|
Prescription Fees | 16 | 2022 | 146 | 1.410 |
Why?
|
Costs and Cost Analysis | 13 | 2023 | 1680 | 1.290 |
Why?
|
Lactones | 8 | 2012 | 329 | 1.250 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 17 | 2019 | 1516 | 1.220 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 26 | 2009 | 2282 | 1.200 |
Why?
|
Health Policy | 24 | 2018 | 2661 | 1.190 |
Why?
|
Medication Adherence | 21 | 2021 | 2063 | 1.190 |
Why?
|
Physicians | 24 | 2022 | 4567 | 1.170 |
Why?
|
Research Design | 31 | 2021 | 5984 | 1.170 |
Why?
|
Humans | 547 | 2023 | 744366 | 1.160 |
Why?
|
Clinical Trials as Topic | 20 | 2021 | 7914 | 1.140 |
Why?
|
Research Support as Topic | 7 | 2017 | 705 | 1.130 |
Why?
|
Myocardial Infarction | 37 | 2019 | 11718 | 1.130 |
Why?
|
Comparative Effectiveness Research | 7 | 2017 | 680 | 1.120 |
Why?
|
Adverse Drug Reaction Reporting Systems | 9 | 2012 | 469 | 1.120 |
Why?
|
Osteoporosis | 21 | 2012 | 1579 | 1.110 |
Why?
|
Rare Diseases | 4 | 2018 | 553 | 1.100 |
Why?
|
Hypolipidemic Agents | 10 | 2012 | 604 | 1.090 |
Why?
|
Hypertension | 26 | 2019 | 8479 | 1.080 |
Why?
|
Education, Medical, Continuing | 17 | 2014 | 840 | 1.080 |
Why?
|
Cyclooxygenase 2 Inhibitors | 10 | 2012 | 320 | 1.050 |
Why?
|
Nursing Homes | 34 | 2012 | 1036 | 1.050 |
Why?
|
Aged | 256 | 2021 | 163288 | 1.030 |
Why?
|
Antipsychotic Agents | 16 | 2018 | 3057 | 1.020 |
Why?
|
Frail Elderly | 7 | 2019 | 693 | 1.000 |
Why?
|
Viral Vaccines | 2 | 2020 | 636 | 1.000 |
Why?
|
Sulfones | 8 | 2012 | 436 | 0.950 |
Why?
|
National Institutes of Health (U.S.) | 10 | 2020 | 780 | 0.950 |
Why?
|
Anticoagulants | 17 | 2021 | 4600 | 0.930 |
Why?
|
Cost-Benefit Analysis | 40 | 2017 | 5388 | 0.930 |
Why?
|
Aged, 80 and over | 132 | 2021 | 57776 | 0.930 |
Why?
|
Cardiovascular Agents | 9 | 2015 | 850 | 0.920 |
Why?
|
Moon | 1 | 2023 | 5 | 0.920 |
Why?
|
Cost Savings | 15 | 2020 | 925 | 0.920 |
Why?
|
Evidence-Based Medicine | 18 | 2017 | 3611 | 0.910 |
Why?
|
Nephrology | 6 | 2007 | 263 | 0.910 |
Why?
|
Insurance, Health, Reimbursement | 7 | 2017 | 397 | 0.910 |
Why?
|
Medicare Part D | 5 | 2020 | 328 | 0.890 |
Why?
|
Conflict of Interest | 6 | 2015 | 544 | 0.880 |
Why?
|
Nonprescription Drugs | 5 | 2022 | 116 | 0.880 |
Why?
|
Hemophilia A | 9 | 2017 | 351 | 0.870 |
Why?
|
Diffusion of Innovation | 6 | 2013 | 725 | 0.860 |
Why?
|
Kidney Failure, Chronic | 12 | 2011 | 2535 | 0.830 |
Why?
|
Drug Substitution | 3 | 2022 | 281 | 0.830 |
Why?
|
Medicare | 38 | 2021 | 6566 | 0.830 |
Why?
|
Renal Dialysis | 9 | 2011 | 1783 | 0.820 |
Why?
|
Randomized Controlled Trials as Topic | 31 | 2018 | 9955 | 0.820 |
Why?
|
Commerce | 6 | 2023 | 592 | 0.810 |
Why?
|
Antidepressive Agents | 17 | 2016 | 2838 | 0.780 |
Why?
|
Herpes Zoster Vaccine | 1 | 2021 | 47 | 0.780 |
Why?
|
Civil Rights | 2 | 2015 | 132 | 0.780 |
Why?
|
Hyperlipidemias | 4 | 2009 | 789 | 0.750 |
Why?
|
Patient Education as Topic | 19 | 2012 | 2278 | 0.740 |
Why?
|
Immunization Schedule | 1 | 2021 | 221 | 0.740 |
Why?
|
Pennsylvania | 23 | 2011 | 613 | 0.740 |
Why?
|
Insurance Claim Review | 11 | 2019 | 720 | 0.730 |
Why?
|
Liability, Legal | 4 | 2012 | 213 | 0.700 |
Why?
|
Risk | 28 | 2017 | 9688 | 0.690 |
Why?
|
Science | 2 | 2017 | 241 | 0.680 |
Why?
|
Coronavirus Infections | 4 | 2020 | 3135 | 0.680 |
Why?
|
Benzimidazoles | 6 | 2015 | 850 | 0.680 |
Why?
|
Herpes Zoster | 1 | 2021 | 264 | 0.670 |
Why?
|
Anticonvulsants | 8 | 2015 | 1916 | 0.670 |
Why?
|
Hip Fractures | 6 | 2015 | 955 | 0.670 |
Why?
|
Female | 262 | 2022 | 380193 | 0.670 |
Why?
|
beta-Alanine | 4 | 2014 | 74 | 0.670 |
Why?
|
Male | 247 | 2022 | 350115 | 0.660 |
Why?
|
Intellectual Property | 4 | 2021 | 31 | 0.650 |
Why?
|
Adrenergic beta-Antagonists | 12 | 2014 | 1240 | 0.650 |
Why?
|
Cohort Studies | 82 | 2022 | 40559 | 0.630 |
Why?
|
Simvastatin | 2 | 2012 | 360 | 0.630 |
Why?
|
Pyridones | 6 | 2021 | 711 | 0.630 |
Why?
|
Angiotensin Receptor Antagonists | 4 | 2019 | 923 | 0.620 |
Why?
|
Pneumonia, Viral | 3 | 2020 | 3242 | 0.620 |
Why?
|
Health Expenditures | 12 | 2018 | 2349 | 0.610 |
Why?
|
Therapeutic Equivalency | 7 | 2017 | 141 | 0.610 |
Why?
|
Drugs, Investigational | 5 | 2020 | 214 | 0.600 |
Why?
|
Pyrazoles | 11 | 2021 | 1972 | 0.600 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 8 | 2018 | 451 | 0.600 |
Why?
|
Drug Repositioning | 2 | 2020 | 230 | 0.590 |
Why?
|
Persuasive Communication | 2 | 2017 | 59 | 0.580 |
Why?
|
Factor VIIa | 3 | 2017 | 101 | 0.580 |
Why?
|
Investments | 2 | 2023 | 143 | 0.580 |
Why?
|
Warfarin | 12 | 2021 | 1497 | 0.570 |
Why?
|
Pyridines | 7 | 2021 | 2825 | 0.560 |
Why?
|
Bone Density Conservation Agents | 8 | 2015 | 772 | 0.560 |
Why?
|
Capital Financing | 2 | 2021 | 58 | 0.560 |
Why?
|
Homes for the Aged | 14 | 1999 | 260 | 0.560 |
Why?
|
History, 20th Century | 14 | 2021 | 2740 | 0.550 |
Why?
|
Morpholines | 4 | 2014 | 571 | 0.540 |
Why?
|
Injections, Intramuscular | 1 | 2017 | 552 | 0.540 |
Why?
|
Public Sector | 4 | 2021 | 265 | 0.540 |
Why?
|
Atrial Fibrillation | 11 | 2021 | 5035 | 0.530 |
Why?
|
Hypoglycemic Agents | 12 | 2022 | 2873 | 0.530 |
Why?
|
Treatment Refusal | 7 | 2007 | 421 | 0.530 |
Why?
|
Dystrophin | 1 | 2016 | 285 | 0.520 |
Why?
|
Quinolines | 3 | 2017 | 732 | 0.520 |
Why?
|
Supreme Court Decisions | 3 | 2013 | 128 | 0.510 |
Why?
|
Antidepressive Agents, Tricyclic | 4 | 2014 | 434 | 0.510 |
Why?
|
Benzothiadiazines | 5 | 2001 | 32 | 0.500 |
Why?
|
Psychomotor Performance | 1 | 2023 | 1901 | 0.490 |
Why?
|
Muscular Dystrophies | 1 | 2017 | 393 | 0.490 |
Why?
|
Azetidines | 2 | 2012 | 142 | 0.490 |
Why?
|
Thiophenes | 4 | 2014 | 589 | 0.490 |
Why?
|
Biological Products | 5 | 2021 | 860 | 0.490 |
Why?
|
Inappropriate Prescribing | 1 | 2017 | 202 | 0.490 |
Why?
|
Influenza Vaccines | 2 | 2021 | 738 | 0.490 |
Why?
|
Disclosure | 4 | 2021 | 736 | 0.490 |
Why?
|
Sulfonamides | 5 | 2015 | 1940 | 0.480 |
Why?
|
Organizations, Nonprofit | 3 | 2017 | 104 | 0.480 |
Why?
|
Polypharmacy | 6 | 2012 | 294 | 0.480 |
Why?
|
Sodium Chloride Symporter Inhibitors | 5 | 2001 | 76 | 0.480 |
Why?
|
Muscular Dystrophy, Duchenne | 1 | 2016 | 256 | 0.470 |
Why?
|
Methylergonovine | 1 | 2013 | 6 | 0.470 |
Why?
|
Plasma Substitutes | 2 | 2003 | 57 | 0.470 |
Why?
|
Physicians, Family | 6 | 2009 | 345 | 0.470 |
Why?
|
Hydrochlorothiazide | 2 | 2009 | 98 | 0.460 |
Why?
|
Epinephrine | 1 | 2017 | 792 | 0.460 |
Why?
|
Coronary Artery Bypass | 5 | 2007 | 2288 | 0.460 |
Why?
|
Cardiovascular Diseases | 21 | 2018 | 15160 | 0.450 |
Why?
|
History, 21st Century | 9 | 2021 | 1534 | 0.450 |
Why?
|
Pandemics | 5 | 2021 | 8385 | 0.450 |
Why?
|
Logistic Models | 38 | 2015 | 13409 | 0.450 |
Why?
|
Cholinergic Antagonists | 6 | 2002 | 165 | 0.440 |
Why?
|
Analgesics, Opioid | 7 | 2022 | 3677 | 0.440 |
Why?
|
Anti-Ulcer Agents | 4 | 2010 | 119 | 0.440 |
Why?
|
Oxytocics | 1 | 2013 | 68 | 0.440 |
Why?
|
Depressive Disorder | 10 | 2014 | 3747 | 0.440 |
Why?
|
Abnormalities, Drug-Induced | 2 | 2015 | 317 | 0.440 |
Why?
|
Middle Aged | 126 | 2021 | 213390 | 0.440 |
Why?
|
Anticholesteremic Agents | 7 | 2017 | 979 | 0.430 |
Why?
|
Comorbidity | 20 | 2018 | 10388 | 0.430 |
Why?
|
Referral and Consultation | 6 | 2010 | 3531 | 0.430 |
Why?
|
Patient Participation | 5 | 2015 | 1457 | 0.430 |
Why?
|
Insurance Claim Reporting | 5 | 2007 | 163 | 0.420 |
Why?
|
Nebulizers and Vaporizers | 3 | 2022 | 139 | 0.420 |
Why?
|
Influenza, Human | 2 | 2021 | 1479 | 0.420 |
Why?
|
Risk Assessment | 28 | 2021 | 23336 | 0.420 |
Why?
|
Complementary Therapies | 2 | 2015 | 486 | 0.410 |
Why?
|
Databases, Factual | 18 | 2021 | 7730 | 0.410 |
Why?
|
Peptic Ulcer | 3 | 2009 | 223 | 0.410 |
Why?
|
Communication | 10 | 2022 | 3750 | 0.410 |
Why?
|
Health Services Research | 12 | 2016 | 1836 | 0.400 |
Why?
|
Cost Control | 10 | 2021 | 624 | 0.390 |
Why?
|
Dietary Supplements | 3 | 2022 | 3296 | 0.390 |
Why?
|
Kidney Diseases | 5 | 2007 | 2148 | 0.390 |
Why?
|
Peritoneal Dialysis | 2 | 2002 | 147 | 0.390 |
Why?
|
Medication Systems, Hospital | 4 | 2005 | 158 | 0.390 |
Why?
|
Clozapine | 4 | 2007 | 498 | 0.380 |
Why?
|
Cyclohexanecarboxylic Acids | 1 | 2011 | 141 | 0.380 |
Why?
|
Thalidomide | 2 | 2016 | 890 | 0.380 |
Why?
|
Diphosphonates | 2 | 2015 | 623 | 0.380 |
Why?
|
Hospitalization | 23 | 2015 | 10259 | 0.380 |
Why?
|
Patient Discharge | 5 | 2018 | 3318 | 0.380 |
Why?
|
Thiazides | 1 | 2010 | 18 | 0.380 |
Why?
|
Quality Assurance, Health Care | 8 | 2010 | 2212 | 0.370 |
Why?
|
Physician-Patient Relations | 8 | 2018 | 3229 | 0.370 |
Why?
|
Hypnotics and Sedatives | 7 | 2017 | 1162 | 0.370 |
Why?
|
Risk Factors | 65 | 2018 | 72296 | 0.370 |
Why?
|
Lipoproteins, HDL | 2 | 2012 | 638 | 0.370 |
Why?
|
Bacteriuria | 3 | 1996 | 102 | 0.370 |
Why?
|
Economic Competition | 6 | 2018 | 214 | 0.360 |
Why?
|
Authorship | 2 | 2012 | 271 | 0.360 |
Why?
|
Arthritis, Rheumatoid | 14 | 2008 | 3712 | 0.360 |
Why?
|
Amines | 1 | 2011 | 276 | 0.360 |
Why?
|
Politics | 5 | 2020 | 791 | 0.360 |
Why?
|
Blood Coagulation Factors | 3 | 2017 | 355 | 0.360 |
Why?
|
Lipoproteins, LDL | 2 | 2012 | 640 | 0.360 |
Why?
|
Decision Support Systems, Clinical | 4 | 2008 | 1164 | 0.360 |
Why?
|
Time Factors | 30 | 2021 | 40075 | 0.360 |
Why?
|
Osteoporotic Fractures | 1 | 2015 | 401 | 0.350 |
Why?
|
Consumer Product Safety | 5 | 2022 | 122 | 0.350 |
Why?
|
Antirheumatic Agents | 10 | 2008 | 1338 | 0.350 |
Why?
|
Data Collection | 6 | 2013 | 3339 | 0.350 |
Why?
|
Deductibles and Coinsurance | 5 | 2021 | 316 | 0.350 |
Why?
|
Retrospective Studies | 58 | 2023 | 77460 | 0.350 |
Why?
|
Postpartum Hemorrhage | 1 | 2013 | 258 | 0.350 |
Why?
|
Ticlopidine | 4 | 2012 | 899 | 0.350 |
Why?
|
Bronchodilator Agents | 2 | 2022 | 502 | 0.350 |
Why?
|
Angina, Unstable | 3 | 2003 | 926 | 0.350 |
Why?
|
Postoperative Hemorrhage | 2 | 2003 | 412 | 0.350 |
Why?
|
Health Services for the Aged | 5 | 2007 | 269 | 0.340 |
Why?
|
Platelet Aggregation Inhibitors | 5 | 2013 | 3070 | 0.340 |
Why?
|
Cost Sharing | 8 | 2015 | 407 | 0.340 |
Why?
|
Epidemiologic Methods | 11 | 2012 | 1364 | 0.340 |
Why?
|
Erythropoietin | 3 | 2011 | 726 | 0.340 |
Why?
|
Bibliometrics | 2 | 2013 | 339 | 0.340 |
Why?
|
Digoxin | 3 | 2004 | 250 | 0.340 |
Why?
|
Isoenzymes | 3 | 2004 | 1728 | 0.340 |
Why?
|
Insurance, Health | 6 | 2018 | 2494 | 0.340 |
Why?
|
Fluorobenzenes | 1 | 2011 | 183 | 0.330 |
Why?
|
Education, Medical | 7 | 2015 | 1722 | 0.330 |
Why?
|
Embolism | 1 | 2012 | 408 | 0.330 |
Why?
|
Sample Size | 5 | 2021 | 845 | 0.330 |
Why?
|
Quality Indicators, Health Care | 4 | 2012 | 1831 | 0.320 |
Why?
|
Case-Control Studies | 26 | 2014 | 21748 | 0.320 |
Why?
|
Propensity Score | 10 | 2015 | 1781 | 0.320 |
Why?
|
Hemostatics | 1 | 2011 | 229 | 0.320 |
Why?
|
Multivariate Analysis | 21 | 2016 | 12244 | 0.320 |
Why?
|
Propranolol | 1 | 2010 | 502 | 0.320 |
Why?
|
Health Knowledge, Attitudes, Practice | 10 | 2019 | 3922 | 0.320 |
Why?
|
Mortality | 10 | 2012 | 2864 | 0.310 |
Why?
|
Benzodiazepines | 8 | 2017 | 1101 | 0.310 |
Why?
|
Industry | 1 | 2010 | 365 | 0.310 |
Why?
|
Insurance Coverage | 6 | 2022 | 1900 | 0.310 |
Why?
|
Reminder Systems | 3 | 2014 | 371 | 0.310 |
Why?
|
Hip Prosthesis | 1 | 2013 | 917 | 0.300 |
Why?
|
Computer Communication Networks | 1 | 2009 | 295 | 0.300 |
Why?
|
Dose-Response Relationship, Drug | 16 | 2017 | 10943 | 0.300 |
Why?
|
Antidepressive Agents, Second-Generation | 2 | 2009 | 503 | 0.290 |
Why?
|
Research Subjects | 3 | 2009 | 239 | 0.290 |
Why?
|
Drug Contamination | 1 | 2008 | 147 | 0.290 |
Why?
|
Investigational New Drug Application | 3 | 2018 | 6 | 0.290 |
Why?
|
Policy Making | 5 | 2020 | 554 | 0.290 |
Why?
|
Hydroxychloroquine | 2 | 2021 | 412 | 0.290 |
Why?
|
Managed Care Programs | 6 | 2017 | 950 | 0.290 |
Why?
|
British Columbia | 9 | 2010 | 244 | 0.290 |
Why?
|
Administration, Oral | 12 | 2014 | 3914 | 0.290 |
Why?
|
Academic Medical Centers | 6 | 2015 | 2760 | 0.290 |
Why?
|
Coronary Disease | 8 | 2013 | 6077 | 0.290 |
Why?
|
Information Dissemination | 5 | 2021 | 1099 | 0.290 |
Why?
|
Aprotinin | 1 | 2006 | 88 | 0.290 |
Why?
|
Parkinson Disease, Secondary | 3 | 1995 | 126 | 0.290 |
Why?
|
Natriuretic Agents | 1 | 2006 | 25 | 0.290 |
Why?
|
Hemorrhage | 6 | 2013 | 3461 | 0.280 |
Why?
|
Odds Ratio | 23 | 2014 | 9849 | 0.280 |
Why?
|
Health Communication | 2 | 2019 | 214 | 0.280 |
Why?
|
Adult | 89 | 2019 | 214052 | 0.280 |
Why?
|
Consumer Health Information | 1 | 2009 | 211 | 0.280 |
Why?
|
Anemia, Iron-Deficiency | 2 | 2007 | 365 | 0.270 |
Why?
|
Cross-Sectional Studies | 27 | 2023 | 25039 | 0.270 |
Why?
|
Basal Ganglia Diseases | 3 | 1995 | 149 | 0.270 |
Why?
|
Diuretics | 8 | 2009 | 591 | 0.270 |
Why?
|
Hypercholesterolemia | 5 | 2018 | 1151 | 0.270 |
Why?
|
Factor VIII | 7 | 2005 | 347 | 0.270 |
Why?
|
Publication Bias | 1 | 2006 | 162 | 0.270 |
Why?
|
Heparin | 3 | 2008 | 1637 | 0.270 |
Why?
|
Pregnancy Complications | 3 | 2014 | 2861 | 0.270 |
Why?
|
Cerebrovascular Disorders | 3 | 1997 | 1504 | 0.270 |
Why?
|
Opioid-Related Disorders | 1 | 2020 | 2064 | 0.270 |
Why?
|
Practice Guidelines as Topic | 14 | 2014 | 7282 | 0.270 |
Why?
|
Drug Monitoring | 6 | 2021 | 956 | 0.260 |
Why?
|
Treatment Outcome | 37 | 2018 | 63107 | 0.260 |
Why?
|
gamma-Aminobutyric Acid | 1 | 2011 | 1121 | 0.260 |
Why?
|
Omeprazole | 1 | 2006 | 112 | 0.260 |
Why?
|
Muscular Diseases | 1 | 2010 | 555 | 0.260 |
Why?
|
Hemarthrosis | 1 | 2005 | 38 | 0.260 |
Why?
|
Quality Improvement | 2 | 2019 | 3749 | 0.260 |
Why?
|
Psychotropic Drugs | 8 | 2005 | 894 | 0.260 |
Why?
|
Budgets | 2 | 2017 | 229 | 0.260 |
Why?
|
Medication Systems | 1 | 2005 | 31 | 0.260 |
Why?
|
Coronary Artery Disease | 5 | 2014 | 6486 | 0.260 |
Why?
|
Anti-Bacterial Agents | 9 | 2016 | 7182 | 0.260 |
Why?
|
Age Factors | 30 | 2016 | 18373 | 0.260 |
Why?
|
Stroke | 10 | 2021 | 9981 | 0.260 |
Why?
|
Pharmacy | 2 | 2022 | 91 | 0.260 |
Why?
|
Cost of Illness | 6 | 2017 | 1860 | 0.260 |
Why?
|
Regression Analysis | 14 | 2012 | 6459 | 0.260 |
Why?
|
Technology Transfer | 1 | 2005 | 44 | 0.260 |
Why?
|
Pharmaceutical Services | 3 | 2007 | 140 | 0.260 |
Why?
|
Medical Assistance | 2 | 2012 | 104 | 0.250 |
Why?
|
Health Services Accessibility | 4 | 2020 | 5135 | 0.250 |
Why?
|
Marketing of Health Services | 2 | 2017 | 153 | 0.250 |
Why?
|
Stents | 2 | 2014 | 3282 | 0.250 |
Why?
|
Antitubercular Agents | 1 | 2013 | 1320 | 0.250 |
Why?
|
Tuberculosis, Multidrug-Resistant | 1 | 2013 | 912 | 0.250 |
Why?
|
Diabetes Mellitus | 8 | 2015 | 5749 | 0.250 |
Why?
|
Drug Interactions | 9 | 2013 | 1460 | 0.250 |
Why?
|
Electric Stimulation Therapy | 1 | 2010 | 605 | 0.250 |
Why?
|
Iatrogenic Disease | 1 | 2008 | 547 | 0.250 |
Why?
|
Pravastatin | 2 | 2006 | 395 | 0.250 |
Why?
|
Fractures, Spontaneous | 4 | 2007 | 230 | 0.250 |
Why?
|
Geriatrics | 3 | 2005 | 397 | 0.250 |
Why?
|
Venous Thrombosis | 3 | 2017 | 1239 | 0.250 |
Why?
|
Immunosuppressive Agents | 4 | 2016 | 4153 | 0.250 |
Why?
|
Activities of Daily Living | 4 | 2019 | 2419 | 0.250 |
Why?
|
Health Care Costs | 9 | 2015 | 3208 | 0.250 |
Why?
|
Research | 6 | 2021 | 1999 | 0.240 |
Why?
|
Models, Economic | 5 | 2015 | 712 | 0.240 |
Why?
|
Students, Medical | 6 | 2015 | 1862 | 0.240 |
Why?
|
Economics, Pharmaceutical | 2 | 2004 | 87 | 0.240 |
Why?
|
Antifibrinolytic Agents | 1 | 2006 | 254 | 0.240 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 5223 | 0.240 |
Why?
|
Angioplasty, Balloon, Coronary | 3 | 2014 | 1873 | 0.240 |
Why?
|
Fees, Pharmaceutical | 5 | 2016 | 64 | 0.240 |
Why?
|
Health Care Sector | 1 | 2006 | 194 | 0.240 |
Why?
|
Tissue Plasminogen Activator | 2 | 2004 | 1261 | 0.240 |
Why?
|
Epilepsy | 4 | 2015 | 3310 | 0.240 |
Why?
|
Kidney | 4 | 2006 | 7184 | 0.230 |
Why?
|
Anti-Arrhythmia Agents | 2 | 2008 | 789 | 0.230 |
Why?
|
Parasympatholytics | 2 | 2002 | 91 | 0.230 |
Why?
|
Glaucoma | 5 | 2011 | 1159 | 0.230 |
Why?
|
Markov Chains | 9 | 2015 | 969 | 0.230 |
Why?
|
Protein C | 1 | 2004 | 138 | 0.230 |
Why?
|
Cardiac Surgical Procedures | 2 | 2018 | 3537 | 0.230 |
Why?
|
Patient Selection | 8 | 2008 | 4216 | 0.230 |
Why?
|
Cardiology | 2 | 2014 | 1668 | 0.230 |
Why?
|
Endpoint Determination | 3 | 2017 | 601 | 0.230 |
Why?
|
Public Health | 4 | 2020 | 2602 | 0.230 |
Why?
|
Heptanoic Acids | 1 | 2005 | 343 | 0.220 |
Why?
|
Decision Making | 14 | 2022 | 3888 | 0.220 |
Why?
|
Attitude of Health Personnel | 11 | 2015 | 3841 | 0.220 |
Why?
|
Direct Service Costs | 1 | 2002 | 62 | 0.220 |
Why?
|
Plant Preparations | 1 | 2003 | 94 | 0.220 |
Why?
|
Biotechnology | 1 | 2005 | 281 | 0.220 |
Why?
|
Arthroplasty, Replacement, Hip | 1 | 2013 | 1462 | 0.220 |
Why?
|
Intraoperative Care | 2 | 2003 | 767 | 0.220 |
Why?
|
Death, Sudden, Cardiac | 2 | 2009 | 1541 | 0.220 |
Why?
|
Dopamine Agonists | 1 | 2005 | 355 | 0.220 |
Why?
|
Health Services Misuse | 4 | 2003 | 243 | 0.220 |
Why?
|
Quality-Adjusted Life Years | 9 | 2013 | 1683 | 0.210 |
Why?
|
Legislation, Food | 1 | 2022 | 17 | 0.210 |
Why?
|
Aging | 8 | 2001 | 8664 | 0.210 |
Why?
|
Diagnostic Tests, Routine | 2 | 2012 | 783 | 0.210 |
Why?
|
Glaucoma, Open-Angle | 2 | 2000 | 706 | 0.210 |
Why?
|
Interprofessional Relations | 5 | 2017 | 1011 | 0.210 |
Why?
|
Geriatric Assessment | 4 | 2019 | 1372 | 0.210 |
Why?
|
Acute Coronary Syndrome | 2 | 2013 | 2337 | 0.210 |
Why?
|
Confidentiality | 3 | 2015 | 612 | 0.210 |
Why?
|
Miotics | 2 | 2000 | 9 | 0.210 |
Why?
|
Medication Errors | 4 | 2009 | 798 | 0.210 |
Why?
|
Drug Therapy, Computer-Assisted | 1 | 2003 | 204 | 0.210 |
Why?
|
Thrombolytic Therapy | 3 | 2004 | 2162 | 0.210 |
Why?
|
Hospital Departments | 1 | 2002 | 137 | 0.210 |
Why?
|
Secondary Prevention | 5 | 2015 | 1530 | 0.210 |
Why?
|
Phosphorus | 1 | 2003 | 338 | 0.200 |
Why?
|
Health Maintenance Organizations | 3 | 2004 | 642 | 0.200 |
Why?
|
Proportional Hazards Models | 16 | 2016 | 12356 | 0.200 |
Why?
|
Heart Failure | 8 | 2008 | 10895 | 0.200 |
Why?
|
Drug Packaging | 2 | 2014 | 39 | 0.200 |
Why?
|
Disorders of Excessive Somnolence | 1 | 2005 | 271 | 0.200 |
Why?
|
Kidney Function Tests | 4 | 2007 | 683 | 0.200 |
Why?
|
Narcotics | 1 | 2004 | 343 | 0.200 |
Why?
|
Dopamine Antagonists | 1 | 2002 | 296 | 0.200 |
Why?
|
Cholesterol Ester Transfer Proteins | 2 | 2017 | 110 | 0.200 |
Why?
|
Internal Medicine | 3 | 2019 | 1009 | 0.200 |
Why?
|
Hyperparathyroidism | 1 | 2003 | 339 | 0.200 |
Why?
|
Periodicals as Topic | 2 | 2012 | 1431 | 0.200 |
Why?
|
Accidental Falls | 5 | 2008 | 1062 | 0.200 |
Why?
|
Preventive Health Services | 2 | 2007 | 575 | 0.200 |
Why?
|
Knee | 1 | 2003 | 274 | 0.200 |
Why?
|
Insulin | 4 | 2016 | 6582 | 0.200 |
Why?
|
Muscle, Skeletal | 1 | 2016 | 4925 | 0.200 |
Why?
|
Cholesterol, LDL | 1 | 2011 | 2355 | 0.200 |
Why?
|
Drug Therapy, Combination | 14 | 2015 | 6489 | 0.200 |
Why?
|
Muscarinic Antagonists | 1 | 2002 | 137 | 0.190 |
Why?
|
Pulmonary Embolism | 3 | 2017 | 2375 | 0.190 |
Why?
|
Chronic Disease | 12 | 2014 | 9145 | 0.190 |
Why?
|
Kidney Transplantation | 3 | 2007 | 4251 | 0.190 |
Why?
|
Bone Density | 5 | 2008 | 3468 | 0.190 |
Why?
|
Choice Behavior | 2 | 2019 | 802 | 0.190 |
Why?
|
Ciprofloxacin | 2 | 2012 | 315 | 0.190 |
Why?
|
Heart Defects, Congenital | 2 | 2014 | 4583 | 0.190 |
Why?
|
Inpatients | 3 | 2007 | 2518 | 0.190 |
Why?
|
C-Reactive Protein | 2 | 2011 | 3778 | 0.190 |
Why?
|
Hospitals | 4 | 2011 | 3954 | 0.190 |
Why?
|
Social Control, Formal | 2 | 2021 | 110 | 0.190 |
Why?
|
Thiazolidinediones | 4 | 2014 | 476 | 0.190 |
Why?
|
Pharmacies | 3 | 2015 | 150 | 0.190 |
Why?
|
Statistics as Topic | 4 | 2018 | 2373 | 0.190 |
Why?
|
Health Services Needs and Demand | 3 | 2020 | 1410 | 0.190 |
Why?
|
Health Benefit Plans, Employee | 2 | 2015 | 332 | 0.190 |
Why?
|
Guideline Adherence | 6 | 2014 | 2265 | 0.190 |
Why?
|
Antifungal Agents | 1 | 2005 | 729 | 0.190 |
Why?
|
Confidence Intervals | 8 | 2014 | 2971 | 0.180 |
Why?
|
Quality of Health Care | 7 | 2012 | 4369 | 0.180 |
Why?
|
Antiparkinson Agents | 2 | 2005 | 184 | 0.180 |
Why?
|
Advisory Committees | 3 | 2016 | 775 | 0.180 |
Why?
|
Medical Records | 7 | 2005 | 1413 | 0.180 |
Why?
|
Renal Replacement Therapy | 1 | 2002 | 257 | 0.180 |
Why?
|
Internship and Residency | 6 | 2022 | 5791 | 0.180 |
Why?
|
Sex Distribution | 8 | 2016 | 2297 | 0.180 |
Why?
|
Patient Admission | 4 | 2004 | 1380 | 0.180 |
Why?
|
Alzheimer Disease | 3 | 2022 | 8038 | 0.180 |
Why?
|
Death, Sudden | 1 | 2002 | 302 | 0.180 |
Why?
|
Patient Preference | 2 | 2019 | 889 | 0.180 |
Why?
|
Models, Econometric | 3 | 2009 | 218 | 0.180 |
Why?
|
Patient Acceptance of Health Care | 5 | 2017 | 3020 | 0.180 |
Why?
|
Hepatitis C, Chronic | 2 | 2020 | 1031 | 0.170 |
Why?
|
Public Opinion | 2 | 2019 | 477 | 0.170 |
Why?
|
Central Nervous System Diseases | 1 | 2004 | 518 | 0.170 |
Why?
|
Sentinel Surveillance | 2 | 2013 | 281 | 0.170 |
Why?
|
Follow-Up Studies | 25 | 2018 | 39052 | 0.170 |
Why?
|
Lung Neoplasms | 2 | 2023 | 13104 | 0.170 |
Why?
|
Decision Support Techniques | 6 | 2009 | 1956 | 0.170 |
Why?
|
Vascular Diseases | 1 | 2008 | 1161 | 0.170 |
Why?
|
Depression | 5 | 2007 | 7759 | 0.170 |
Why?
|
Medicare Part B | 2 | 2012 | 108 | 0.170 |
Why?
|
Fruit | 2 | 1996 | 1142 | 0.170 |
Why?
|
Medical Order Entry Systems | 2 | 2007 | 545 | 0.170 |
Why?
|
Osteoarthritis | 5 | 2006 | 1036 | 0.170 |
Why?
|
Financial Management | 1 | 2020 | 160 | 0.170 |
Why?
|
State Medicine | 1 | 2020 | 217 | 0.170 |
Why?
|
Smoking | 5 | 2016 | 8987 | 0.170 |
Why?
|
Health Care Reform | 5 | 2018 | 1261 | 0.170 |
Why?
|
Patient-Centered Care | 3 | 2014 | 1438 | 0.170 |
Why?
|
Pyrimidines | 1 | 2011 | 2943 | 0.160 |
Why?
|
Long-Term Care | 6 | 2001 | 607 | 0.160 |
Why?
|
Pyrroles | 1 | 2005 | 1146 | 0.160 |
Why?
|
Drug Combinations | 3 | 2012 | 1958 | 0.160 |
Why?
|
Chloroquine | 1 | 2020 | 279 | 0.160 |
Why?
|
Bioethical Issues | 2 | 2015 | 124 | 0.160 |
Why?
|
Information Systems | 2 | 1999 | 410 | 0.160 |
Why?
|
Altitude | 2 | 2011 | 161 | 0.160 |
Why?
|
Adenosine Monophosphate | 1 | 2020 | 275 | 0.160 |
Why?
|
Pharmacy Service, Hospital | 4 | 2002 | 133 | 0.160 |
Why?
|
Incidence | 16 | 2017 | 20952 | 0.160 |
Why?
|
Home Nursing | 1 | 1998 | 92 | 0.160 |
Why?
|
Socioeconomic Factors | 14 | 2016 | 7785 | 0.160 |
Why?
|
Delivery of Health Care | 6 | 2022 | 5321 | 0.160 |
Why?
|
Adrenal Cortex Hormones | 3 | 2006 | 1856 | 0.160 |
Why?
|
Breast Neoplasms | 6 | 2006 | 20824 | 0.160 |
Why?
|
Mass Screening | 8 | 2007 | 5253 | 0.160 |
Why?
|
Thrombosis | 1 | 2012 | 2968 | 0.160 |
Why?
|
Gift Giving | 2 | 2015 | 80 | 0.160 |
Why?
|
Tamoxifen | 1 | 2003 | 981 | 0.160 |
Why?
|
Alanine | 1 | 2020 | 572 | 0.160 |
Why?
|
Lobbying | 1 | 2018 | 32 | 0.160 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2006 | 1572 | 0.160 |
Why?
|
Gastrointestinal Agents | 1 | 2003 | 494 | 0.160 |
Why?
|
Ownership | 1 | 2020 | 332 | 0.150 |
Why?
|
Phentermine | 1 | 1997 | 33 | 0.150 |
Why?
|
Pyuria | 2 | 1995 | 30 | 0.150 |
Why?
|
Longitudinal Studies | 9 | 2019 | 13991 | 0.150 |
Why?
|
Fenfluramine | 1 | 1997 | 59 | 0.150 |
Why?
|
Coronary Angiography | 3 | 2007 | 4576 | 0.150 |
Why?
|
Enalapril | 1 | 1999 | 327 | 0.150 |
Why?
|
Dopamine Agents | 2 | 1995 | 189 | 0.150 |
Why?
|
Anti-Asthmatic Agents | 1 | 2022 | 536 | 0.150 |
Why?
|
Ramipril | 1 | 2018 | 95 | 0.150 |
Why?
|
Medical Staff, Hospital | 5 | 2007 | 601 | 0.150 |
Why?
|
Hemophilia B | 1 | 2017 | 81 | 0.150 |
Why?
|
Trust | 2 | 2016 | 505 | 0.150 |
Why?
|
Urinary Incontinence | 1 | 2002 | 496 | 0.150 |
Why?
|
Risk Management | 2 | 2015 | 571 | 0.150 |
Why?
|
Spain | 2 | 2016 | 465 | 0.150 |
Why?
|
Drug Administration Schedule | 10 | 2014 | 4933 | 0.150 |
Why?
|
Research Personnel | 2 | 2015 | 573 | 0.150 |
Why?
|
Dexfenfluramine | 2 | 2007 | 8 | 0.150 |
Why?
|
Gastrointestinal Hemorrhage | 2 | 2012 | 1131 | 0.150 |
Why?
|
Appetite Depressants | 1 | 1997 | 110 | 0.150 |
Why?
|
Bone Marrow Transplantation | 1 | 2005 | 2765 | 0.150 |
Why?
|
Europe | 3 | 2011 | 3338 | 0.150 |
Why?
|
Patients | 4 | 2010 | 900 | 0.150 |
Why?
|
Legislation as Topic | 1 | 2017 | 80 | 0.140 |
Why?
|
Risk Adjustment | 5 | 2011 | 594 | 0.140 |
Why?
|
Ophthalmic Solutions | 2 | 2000 | 317 | 0.140 |
Why?
|
Proton Pump Inhibitors | 3 | 2010 | 526 | 0.140 |
Why?
|
Republic of Korea | 2 | 2016 | 538 | 0.140 |
Why?
|
Reproducibility of Results | 11 | 2017 | 19905 | 0.140 |
Why?
|
Netherlands | 7 | 2008 | 2170 | 0.140 |
Why?
|
Codon, Terminator | 1 | 2016 | 127 | 0.140 |
Why?
|
Negotiating | 2 | 2016 | 133 | 0.140 |
Why?
|
Gastrointestinal Diseases | 3 | 2005 | 1170 | 0.140 |
Why?
|
Gout | 2 | 2007 | 573 | 0.140 |
Why?
|
Age Distribution | 8 | 2016 | 2902 | 0.140 |
Why?
|
Biomarkers, Pharmacological | 1 | 2017 | 162 | 0.140 |
Why?
|
Predictive Value of Tests | 13 | 2017 | 15078 | 0.140 |
Why?
|
Arrhythmias, Cardiac | 2 | 2007 | 2269 | 0.140 |
Why?
|
Rheumatic Diseases | 1 | 2003 | 593 | 0.140 |
Why?
|
Massachusetts | 15 | 2021 | 8662 | 0.140 |
Why?
|
Diabetes Mellitus, Type 2 | 7 | 2022 | 11726 | 0.140 |
Why?
|
Risk Reduction Behavior | 2 | 2014 | 1125 | 0.140 |
Why?
|
Metoclopramide | 1 | 1995 | 51 | 0.140 |
Why?
|
Drug Information Services | 7 | 1996 | 51 | 0.140 |
Why?
|
Immunization | 1 | 2020 | 1256 | 0.140 |
Why?
|
Postoperative Complications | 1 | 2018 | 15297 | 0.140 |
Why?
|
Medical Audit | 6 | 2007 | 467 | 0.140 |
Why?
|
Anemia | 3 | 2011 | 1503 | 0.140 |
Why?
|
Extrapyramidal Tracts | 1 | 1995 | 18 | 0.130 |
Why?
|
Movement | 1 | 2023 | 1471 | 0.130 |
Why?
|
State Government | 2 | 2016 | 372 | 0.130 |
Why?
|
Pain, Postoperative | 2 | 2016 | 1643 | 0.130 |
Why?
|
Dyspepsia | 1 | 1997 | 116 | 0.130 |
Why?
|
Administration, Inhalation | 3 | 2022 | 1105 | 0.130 |
Why?
|
Capital Expenditures | 1 | 2015 | 29 | 0.130 |
Why?
|
Thiazoles | 3 | 2021 | 1483 | 0.130 |
Why?
|
Histamine H2 Antagonists | 1 | 1997 | 165 | 0.130 |
Why?
|
Carpal Tunnel Syndrome | 1 | 1999 | 300 | 0.130 |
Why?
|
Bacterial Infections | 3 | 2016 | 1401 | 0.130 |
Why?
|
Freedom | 1 | 2015 | 69 | 0.130 |
Why?
|
Health Status | 2 | 2006 | 4034 | 0.130 |
Why?
|
Epidemiologic Research Design | 2 | 2012 | 367 | 0.130 |
Why?
|
Observation | 2 | 2007 | 312 | 0.130 |
Why?
|
Streptokinase | 1 | 1995 | 188 | 0.130 |
Why?
|
Pulmonary Surfactants | 1 | 1996 | 162 | 0.130 |
Why?
|
Ambulatory Care Facilities | 1 | 2001 | 934 | 0.130 |
Why?
|
Adolescent | 31 | 2017 | 85779 | 0.130 |
Why?
|
Levodopa | 1 | 1995 | 219 | 0.130 |
Why?
|
Contraceptives, Oral | 2 | 2016 | 564 | 0.130 |
Why?
|
Health Status Indicators | 2 | 2019 | 970 | 0.130 |
Why?
|
Glucocorticoids | 6 | 2008 | 2108 | 0.130 |
Why?
|
Hematocrit | 4 | 2011 | 636 | 0.130 |
Why?
|
Tooth Extraction | 1 | 2016 | 222 | 0.130 |
Why?
|
Qualitative Research | 4 | 2022 | 2682 | 0.120 |
Why?
|
Algorithms | 6 | 2017 | 13882 | 0.120 |
Why?
|
Young Adult | 21 | 2017 | 56429 | 0.120 |
Why?
|
Travel | 2 | 2017 | 788 | 0.120 |
Why?
|
Patient Simulation | 1 | 2017 | 309 | 0.120 |
Why?
|
Epidemiology | 2 | 2003 | 287 | 0.120 |
Why?
|
Antiviral Agents | 3 | 2020 | 2987 | 0.120 |
Why?
|
Salaries and Fringe Benefits | 2 | 2015 | 264 | 0.120 |
Why?
|
Fibrinolytic Agents | 1 | 2004 | 2158 | 0.120 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2003 | 1524 | 0.120 |
Why?
|
Asthma | 4 | 2022 | 6010 | 0.120 |
Why?
|
Ibuprofen | 1 | 1996 | 236 | 0.120 |
Why?
|
Pharmacists | 5 | 2007 | 248 | 0.120 |
Why?
|
Sex Factors | 11 | 2014 | 10400 | 0.120 |
Why?
|
Private Sector | 3 | 2023 | 392 | 0.120 |
Why?
|
Fluconazole | 2 | 2005 | 146 | 0.120 |
Why?
|
Intraocular Pressure | 1 | 2000 | 1270 | 0.120 |
Why?
|
Blood Donors | 7 | 1993 | 355 | 0.120 |
Why?
|
Database Management Systems | 2 | 2008 | 270 | 0.120 |
Why?
|
Safety-Based Drug Withdrawals | 2 | 2013 | 38 | 0.120 |
Why?
|
Oseltamivir | 1 | 2014 | 75 | 0.120 |
Why?
|
Acetaminophen | 1 | 1998 | 545 | 0.120 |
Why?
|
Lipids | 2 | 2017 | 3307 | 0.120 |
Why?
|
Antineoplastic Agents | 3 | 2016 | 13693 | 0.120 |
Why?
|
Skilled Nursing Facilities | 2 | 1997 | 372 | 0.120 |
Why?
|
Length of Stay | 6 | 2008 | 6311 | 0.120 |
Why?
|
Communication Barriers | 1 | 2017 | 398 | 0.120 |
Why?
|
American Medical Association | 2 | 2011 | 65 | 0.120 |
Why?
|
Canada | 4 | 2017 | 2065 | 0.120 |
Why?
|
Drug Synergism | 2 | 2010 | 1794 | 0.110 |
Why?
|
Health Behavior | 4 | 2011 | 2635 | 0.110 |
Why?
|
Random Allocation | 5 | 2004 | 2428 | 0.110 |
Why?
|
Telephone | 3 | 2012 | 617 | 0.110 |
Why?
|
Fractures, Bone | 6 | 2008 | 1947 | 0.110 |
Why?
|
Patient Rights | 1 | 2014 | 126 | 0.110 |
Why?
|
Medicare Part C | 2 | 2021 | 296 | 0.110 |
Why?
|
Biomedical Research | 3 | 2005 | 3309 | 0.110 |
Why?
|
Internet | 2 | 2017 | 3056 | 0.110 |
Why?
|
Self Administration | 4 | 2007 | 385 | 0.110 |
Why?
|
Nursing Staff | 2 | 1991 | 129 | 0.110 |
Why?
|
Benzoates | 1 | 2014 | 217 | 0.110 |
Why?
|
Blue Cross Blue Shield Insurance Plans | 1 | 2013 | 94 | 0.110 |
Why?
|
Hydrazines | 1 | 2014 | 226 | 0.110 |
Why?
|
Adolescent Psychiatry | 1 | 2014 | 148 | 0.110 |
Why?
|
Sulfanilamides | 1 | 2012 | 15 | 0.110 |
Why?
|
Metformin | 3 | 2014 | 836 | 0.110 |
Why?
|
Ofloxacin | 2 | 2003 | 65 | 0.110 |
Why?
|
Thrombopoietin | 1 | 2014 | 225 | 0.110 |
Why?
|
Prostaglandin-Endoperoxide Synthases | 2 | 2004 | 329 | 0.110 |
Why?
|
Lisinopril | 1 | 2012 | 54 | 0.110 |
Why?
|
Evaluation Studies as Topic | 4 | 2008 | 1681 | 0.110 |
Why?
|
Software | 4 | 2021 | 4441 | 0.110 |
Why?
|
Vaccines | 1 | 2021 | 823 | 0.100 |
Why?
|
Naproxen | 2 | 2003 | 99 | 0.100 |
Why?
|
Contraception | 1 | 2016 | 359 | 0.100 |
Why?
|
Prescriptions | 2 | 2020 | 387 | 0.100 |
Why?
|
Cross-Over Studies | 5 | 2010 | 2029 | 0.100 |
Why?
|
Arthritis | 3 | 2008 | 661 | 0.100 |
Why?
|
Clindamycin | 2 | 1989 | 139 | 0.100 |
Why?
|
Primary Health Care | 5 | 2020 | 4557 | 0.100 |
Why?
|
Ambulatory Care | 3 | 2007 | 2708 | 0.100 |
Why?
|
Brain Ischemia | 3 | 2013 | 3265 | 0.100 |
Why?
|
Schools, Medical | 2 | 2015 | 881 | 0.100 |
Why?
|
Self Care | 3 | 2004 | 786 | 0.100 |
Why?
|
Blood Pressure | 6 | 2008 | 8551 | 0.100 |
Why?
|
Fish Oils | 1 | 2015 | 470 | 0.100 |
Why?
|
Registries | 4 | 2006 | 8091 | 0.100 |
Why?
|
Survival Analysis | 5 | 2006 | 10252 | 0.100 |
Why?
|
Ethylene Glycols | 1 | 2012 | 156 | 0.100 |
Why?
|
Reimbursement, Incentive | 1 | 2017 | 540 | 0.100 |
Why?
|
Uric Acid | 1 | 1997 | 766 | 0.100 |
Why?
|
Tumor Necrosis Factor-alpha | 3 | 2008 | 4424 | 0.100 |
Why?
|
Universities | 2 | 2009 | 951 | 0.100 |
Why?
|
Paroxetine | 1 | 2012 | 182 | 0.100 |
Why?
|
Parkinson Disease | 1 | 2005 | 2775 | 0.100 |
Why?
|
Cathartics | 4 | 1996 | 125 | 0.100 |
Why?
|
Naphthalenes | 1 | 2012 | 194 | 0.100 |
Why?
|
Thromboembolism | 1 | 2017 | 987 | 0.100 |
Why?
|
Heart Diseases | 4 | 2015 | 2789 | 0.100 |
Why?
|
Intention to Treat Analysis | 1 | 2012 | 426 | 0.100 |
Why?
|
Receptors, Fc | 1 | 2014 | 541 | 0.100 |
Why?
|
Clinical Medicine | 1 | 2012 | 147 | 0.100 |
Why?
|
International Classification of Diseases | 3 | 2005 | 867 | 0.100 |
Why?
|
Neoplasms | 7 | 2018 | 21696 | 0.100 |
Why?
|
Sputum | 1 | 2013 | 476 | 0.100 |
Why?
|
Models, Statistical | 10 | 2013 | 5101 | 0.100 |
Why?
|
Nurse Practitioners | 2 | 1991 | 269 | 0.100 |
Why?
|
Cyclooxygenase 2 | 2 | 2004 | 612 | 0.090 |
Why?
|
Income | 2 | 2017 | 1913 | 0.090 |
Why?
|
Pregnancy | 8 | 2016 | 29144 | 0.090 |
Why?
|
Joint Diseases | 2 | 2004 | 479 | 0.090 |
Why?
|
Exons | 1 | 2016 | 2439 | 0.090 |
Why?
|
Women | 1 | 1992 | 230 | 0.090 |
Why?
|
Purpura, Thrombocytopenic, Idiopathic | 1 | 2014 | 233 | 0.090 |
Why?
|
Child | 19 | 2017 | 77709 | 0.090 |
Why?
|
Constipation | 4 | 1997 | 546 | 0.090 |
Why?
|
Developed Countries | 1 | 2013 | 437 | 0.090 |
Why?
|
Iron | 2 | 2010 | 1774 | 0.090 |
Why?
|
Utilization Review | 3 | 2010 | 392 | 0.090 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2014 | 459 | 0.090 |
Why?
|
Recombinant Proteins | 3 | 2017 | 6621 | 0.090 |
Why?
|
Calcium | 1 | 2003 | 5755 | 0.090 |
Why?
|
History, 19th Century | 1 | 2012 | 720 | 0.090 |
Why?
|
Dyslipidemias | 1 | 2017 | 849 | 0.090 |
Why?
|
Equipment Safety | 1 | 2010 | 263 | 0.090 |
Why?
|
Data Interpretation, Statistical | 6 | 2012 | 2716 | 0.090 |
Why?
|
Renin-Angiotensin System | 2 | 2012 | 758 | 0.090 |
Why?
|
Likelihood Functions | 2 | 2004 | 1005 | 0.090 |
Why?
|
Healthcare Disparities | 3 | 2014 | 3154 | 0.090 |
Why?
|
Sensitivity and Specificity | 8 | 2015 | 14723 | 0.090 |
Why?
|
Probability | 2 | 2006 | 2506 | 0.090 |
Why?
|
International Normalized Ratio | 1 | 2011 | 367 | 0.090 |
Why?
|
Poisson Distribution | 3 | 2013 | 513 | 0.090 |
Why?
|
Glomerular Filtration Rate | 4 | 2007 | 2166 | 0.080 |
Why?
|
Teaching | 2 | 2011 | 1174 | 0.080 |
Why?
|
Teaching Materials | 2 | 2005 | 86 | 0.080 |
Why?
|
Medical Record Linkage | 3 | 2015 | 284 | 0.080 |
Why?
|
Attitude to Health | 4 | 2007 | 2052 | 0.080 |
Why?
|
Motivation | 2 | 2009 | 1971 | 0.080 |
Why?
|
Community Pharmacy Services | 1 | 2009 | 46 | 0.080 |
Why?
|
Linear Models | 5 | 2009 | 5953 | 0.080 |
Why?
|
Diagnosis-Related Groups | 3 | 2005 | 455 | 0.080 |
Why?
|
Schizophrenia | 2 | 2005 | 6882 | 0.080 |
Why?
|
Psychotic Disorders | 2 | 2005 | 3046 | 0.080 |
Why?
|
Publications | 1 | 2011 | 195 | 0.080 |
Why?
|
Rhabdomyolysis | 1 | 2010 | 150 | 0.080 |
Why?
|
Lidocaine | 1 | 2012 | 544 | 0.080 |
Why?
|
Truth Disclosure | 1 | 2013 | 436 | 0.080 |
Why?
|
Self Report | 2 | 2019 | 3553 | 0.080 |
Why?
|
Ventricular Dysfunction, Left | 1 | 1999 | 2073 | 0.080 |
Why?
|
Long QT Syndrome | 1 | 2013 | 453 | 0.080 |
Why?
|
Health Care Surveys | 4 | 2019 | 2453 | 0.080 |
Why?
|
Beverages | 1 | 1994 | 821 | 0.080 |
Why?
|
Government Agencies | 1 | 2009 | 156 | 0.080 |
Why?
|
Faculty, Medical | 1 | 2017 | 1181 | 0.080 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2012 | 841 | 0.080 |
Why?
|
Physician's Role | 4 | 2007 | 943 | 0.080 |
Why?
|
Pharmacology, Clinical | 1 | 1987 | 21 | 0.080 |
Why?
|
Heart Conduction System | 1 | 1994 | 1047 | 0.080 |
Why?
|
Dissent and Disputes | 1 | 2009 | 141 | 0.080 |
Why?
|
Medical History Taking | 2 | 1991 | 784 | 0.080 |
Why?
|
Evidence-Based Practice | 1 | 2012 | 501 | 0.080 |
Why?
|
Speech | 1 | 2013 | 541 | 0.080 |
Why?
|
Cesarean Section | 2 | 2016 | 1365 | 0.080 |
Why?
|
Delirium | 2 | 2018 | 1610 | 0.080 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2018 | 1209 | 0.080 |
Why?
|
France | 2 | 2021 | 517 | 0.080 |
Why?
|
Germany | 2 | 2016 | 862 | 0.080 |
Why?
|
Dementia | 6 | 2017 | 2518 | 0.080 |
Why?
|
Seizures | 2 | 2010 | 2859 | 0.080 |
Why?
|
Hospitals, Teaching | 5 | 2001 | 1180 | 0.070 |
Why?
|
Anti-HIV Agents | 1 | 2023 | 4255 | 0.070 |
Why?
|
Aspirin | 5 | 2008 | 3283 | 0.070 |
Why?
|
Mental Health Services | 2 | 2010 | 1644 | 0.070 |
Why?
|
Employer Health Costs | 1 | 2006 | 21 | 0.070 |
Why?
|
Heparin Antagonists | 1 | 2007 | 32 | 0.070 |
Why?
|
Pamphlets | 1 | 2007 | 75 | 0.070 |
Why?
|
Double-Blind Method | 4 | 2011 | 12025 | 0.070 |
Why?
|
Hematinics | 1 | 2010 | 280 | 0.070 |
Why?
|
Fluoridation | 1 | 1986 | 29 | 0.070 |
Why?
|
Licensure, Medical | 1 | 2007 | 62 | 0.070 |
Why?
|
Metronidazole | 2 | 2003 | 217 | 0.070 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 3 | 2018 | 293 | 0.070 |
Why?
|
Federal Government | 2 | 2022 | 260 | 0.070 |
Why?
|
Hypertension, Pulmonary | 1 | 1997 | 1534 | 0.070 |
Why?
|
Actuarial Analysis | 1 | 2006 | 378 | 0.070 |
Why?
|
Sulfoxides | 1 | 2006 | 48 | 0.070 |
Why?
|
Antithrombins | 2 | 2021 | 304 | 0.070 |
Why?
|
Duty to Warn | 1 | 2006 | 30 | 0.070 |
Why?
|
Hypoglycemia | 1 | 1994 | 861 | 0.070 |
Why?
|
Blood Coagulation | 2 | 2008 | 1127 | 0.070 |
Why?
|
2-Pyridinylmethylsulfinylbenzimidazoles | 1 | 2006 | 35 | 0.070 |
Why?
|
Medical Records Systems, Computerized | 3 | 2008 | 1205 | 0.070 |
Why?
|
Community-Institutional Relations | 1 | 2007 | 204 | 0.070 |
Why?
|
Recombinant Fusion Proteins | 1 | 2014 | 3773 | 0.070 |
Why?
|
Deception | 1 | 2006 | 99 | 0.070 |
Why?
|
Anti-Infective Agents | 3 | 2018 | 974 | 0.070 |
Why?
|
Gout Suppressants | 1 | 2007 | 166 | 0.070 |
Why?
|
Fees and Charges | 1 | 2007 | 195 | 0.070 |
Why?
|
Phosphatidylglycerols | 1 | 2005 | 34 | 0.070 |
Why?
|
Benzhydryl Compounds | 1 | 2012 | 845 | 0.070 |
Why?
|
Insurance Benefits | 1 | 2007 | 183 | 0.070 |
Why?
|
Prostate-Specific Antigen | 3 | 2007 | 2494 | 0.070 |
Why?
|
Retreatment | 2 | 2011 | 610 | 0.070 |
Why?
|
Patient Satisfaction | 2 | 2009 | 3395 | 0.070 |
Why?
|
SEER Program | 2 | 2001 | 1507 | 0.070 |
Why?
|
Dextropropoxyphene | 4 | 1987 | 26 | 0.070 |
Why?
|
Deoxycholic Acid | 1 | 2005 | 54 | 0.070 |
Why?
|
Severity of Illness Index | 7 | 2014 | 15535 | 0.070 |
Why?
|
Residence Characteristics | 2 | 2012 | 2050 | 0.070 |
Why?
|
Neuralgia | 1 | 2012 | 570 | 0.070 |
Why?
|
Population Surveillance | 2 | 2011 | 2616 | 0.060 |
Why?
|
Infant, Newborn | 7 | 2017 | 25628 | 0.060 |
Why?
|
Amphotericin B | 1 | 2005 | 137 | 0.060 |
Why?
|
Placebos | 2 | 2006 | 1676 | 0.060 |
Why?
|
Autoantibodies | 2 | 2005 | 2036 | 0.060 |
Why?
|
Factor VII | 1 | 2005 | 139 | 0.060 |
Why?
|
Morbidity | 4 | 1996 | 1768 | 0.060 |
Why?
|
Knee Joint | 2 | 2004 | 1680 | 0.060 |
Why?
|
Half-Life | 2 | 2001 | 661 | 0.060 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2005 | 187 | 0.060 |
Why?
|
Boston | 5 | 2002 | 9312 | 0.060 |
Why?
|
Losartan | 1 | 2006 | 299 | 0.060 |
Why?
|
Analysis of Variance | 5 | 2007 | 6366 | 0.060 |
Why?
|
Hepatitis C | 1 | 2014 | 1591 | 0.060 |
Why?
|
Abdominal Pain | 1 | 1991 | 1064 | 0.060 |
Why?
|
Chemistry, Pharmaceutical | 1 | 2005 | 281 | 0.060 |
Why?
|
Lung Diseases, Obstructive | 1 | 2005 | 316 | 0.060 |
Why?
|
Ranitidine | 1 | 2003 | 34 | 0.060 |
Why?
|
Pharmacokinetics | 2 | 1996 | 88 | 0.060 |
Why?
|
Hyperglycemia | 1 | 1993 | 1373 | 0.060 |
Why?
|
Factor IX | 1 | 2004 | 77 | 0.060 |
Why?
|
Clinical Pharmacy Information Systems | 2 | 1996 | 103 | 0.060 |
Why?
|
Decision Making, Organizational | 1 | 2004 | 139 | 0.060 |
Why?
|
Health Status Disparities | 1 | 2015 | 1796 | 0.060 |
Why?
|
Platelet Transfusion | 1 | 2007 | 314 | 0.060 |
Why?
|
Calcium Channel Agonists | 1 | 2003 | 29 | 0.060 |
Why?
|
Violence | 1 | 2010 | 909 | 0.060 |
Why?
|
Blood Transfusion | 4 | 2000 | 1301 | 0.060 |
Why?
|
Pharmacology | 2 | 1996 | 103 | 0.060 |
Why?
|
Phosphatidylcholines | 1 | 2005 | 411 | 0.060 |
Why?
|
Morale | 1 | 1983 | 12 | 0.060 |
Why?
|
Continuity of Patient Care | 2 | 2008 | 1049 | 0.060 |
Why?
|
Public Health Informatics | 1 | 2004 | 110 | 0.060 |
Why?
|
Cause of Death | 3 | 2012 | 3582 | 0.060 |
Why?
|
Infant | 8 | 2017 | 35134 | 0.060 |
Why?
|
Cannabinoids | 1 | 2005 | 166 | 0.060 |
Why?
|
Prevalence | 8 | 2015 | 15221 | 0.050 |
Why?
|
Scotland | 1 | 2002 | 155 | 0.050 |
Why?
|
Economics, Hospital | 1 | 1985 | 213 | 0.050 |
Why?
|
Ireland | 1 | 2002 | 161 | 0.050 |
Why?
|
Decision Trees | 2 | 2007 | 506 | 0.050 |
Why?
|
Life Tables | 1 | 2002 | 370 | 0.050 |
Why?
|
Child, Preschool | 8 | 2017 | 41005 | 0.050 |
Why?
|
Creatinine | 3 | 2007 | 1919 | 0.050 |
Why?
|
Software Design | 1 | 2002 | 176 | 0.050 |
Why?
|
Blood Component Transfusion | 1 | 2003 | 143 | 0.050 |
Why?
|
Social Class | 2 | 2001 | 1997 | 0.050 |
Why?
|
Diabetic Nephropathies | 2 | 2006 | 984 | 0.050 |
Why?
|
Coronary Vessels | 1 | 2014 | 3107 | 0.050 |
Why?
|
Ethics | 1 | 1982 | 94 | 0.050 |
Why?
|
Ethicists | 1 | 1982 | 37 | 0.050 |
Why?
|
Chlorpropamide | 1 | 2001 | 9 | 0.050 |
Why?
|
Cholesterol | 3 | 2007 | 2919 | 0.050 |
Why?
|
China | 1 | 2008 | 2245 | 0.050 |
Why?
|
Mycobacterium tuberculosis | 1 | 2013 | 1832 | 0.050 |
Why?
|
Philosophy | 1 | 1982 | 66 | 0.050 |
Why?
|
Meperidine | 1 | 2001 | 38 | 0.050 |
Why?
|
New York | 3 | 2021 | 886 | 0.050 |
Why?
|
Sulfonylurea Compounds | 2 | 2014 | 205 | 0.050 |
Why?
|
Amiodarone | 1 | 2003 | 212 | 0.050 |
Why?
|
Prognosis | 6 | 2008 | 29060 | 0.050 |
Why?
|
Erythrocyte Transfusion | 1 | 2007 | 565 | 0.050 |
Why?
|
Delphi Technique | 1 | 2005 | 779 | 0.050 |
Why?
|
Multicenter Studies as Topic | 2 | 2007 | 1677 | 0.050 |
Why?
|
Cooperative Behavior | 2 | 2012 | 1504 | 0.050 |
Why?
|
Program Development | 1 | 2008 | 1316 | 0.050 |
Why?
|
Therapies, Investigational | 1 | 2023 | 112 | 0.050 |
Why?
|
Premature Birth | 1 | 2014 | 1721 | 0.050 |
Why?
|
Suicide, Attempted | 1 | 2010 | 1218 | 0.050 |
Why?
|
Calcitriol | 1 | 2003 | 297 | 0.050 |
Why?
|
Reimbursement Mechanisms | 2 | 2006 | 670 | 0.050 |
Why?
|
Forecasting | 4 | 2020 | 2951 | 0.050 |
Why?
|
National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2021 | 62 | 0.050 |
Why?
|
Prostatic Neoplasms | 1 | 2004 | 11126 | 0.050 |
Why?
|
Retirement | 1 | 1983 | 216 | 0.050 |
Why?
|
Ceftazidime | 1 | 2001 | 69 | 0.050 |
Why?
|
Life Expectancy | 3 | 2005 | 1184 | 0.050 |
Why?
|
HIV Infections | 4 | 2023 | 16715 | 0.050 |
Why?
|
Pharmacogenetics | 1 | 2005 | 674 | 0.050 |
Why?
|
Hospitals, Veterans | 1 | 2004 | 404 | 0.050 |
Why?
|
Mental Disorders | 3 | 2014 | 6598 | 0.050 |
Why?
|
Barbiturates | 1 | 2001 | 114 | 0.050 |
Why?
|
Calibration | 3 | 2010 | 816 | 0.050 |
Why?
|
Legislation, Medical | 1 | 2021 | 100 | 0.050 |
Why?
|
Occupational Health | 1 | 2007 | 808 | 0.050 |
Why?
|
Cluster Analysis | 2 | 2007 | 2715 | 0.050 |
Why?
|
Technology Assessment, Biomedical | 1 | 2003 | 306 | 0.050 |
Why?
|
Molecular Structure | 1 | 2005 | 1899 | 0.050 |
Why?
|
Sleep Initiation and Maintenance Disorders | 2 | 2005 | 1004 | 0.050 |
Why?
|
Prolactin | 1 | 2002 | 669 | 0.050 |
Why?
|
Prospective Studies | 9 | 2012 | 53290 | 0.050 |
Why?
|
Survival Rate | 3 | 2016 | 12788 | 0.050 |
Why?
|
Pregnancy Trimester, First | 2 | 2015 | 853 | 0.050 |
Why?
|
Time | 1 | 2002 | 542 | 0.050 |
Why?
|
Educational Status | 2 | 2007 | 2540 | 0.050 |
Why?
|
Cephalosporins | 1 | 2001 | 204 | 0.050 |
Why?
|
Financial Support | 1 | 2021 | 115 | 0.050 |
Why?
|
Diabetes Complications | 2 | 2015 | 1359 | 0.050 |
Why?
|
Health | 1 | 1983 | 394 | 0.040 |
Why?
|
Disability Evaluation | 2 | 2004 | 1828 | 0.040 |
Why?
|
Dibenzothiazepines | 2 | 2012 | 103 | 0.040 |
Why?
|
Social Responsibility | 1 | 2022 | 388 | 0.040 |
Why?
|
Financing, Organized | 1 | 2021 | 202 | 0.040 |
Why?
|
Interviews as Topic | 2 | 2005 | 2539 | 0.040 |
Why?
|
Medical Oncology | 1 | 2011 | 2267 | 0.040 |
Why?
|
Suicide | 1 | 2010 | 1474 | 0.040 |
Why?
|
Computer Simulation | 2 | 2010 | 6194 | 0.040 |
Why?
|
Vaginal Smears | 1 | 2002 | 511 | 0.040 |
Why?
|
England | 1 | 2020 | 522 | 0.040 |
Why?
|
Arteriovenous Shunt, Surgical | 1 | 2002 | 277 | 0.040 |
Why?
|
Pediatrics | 1 | 2014 | 3475 | 0.040 |
Why?
|
Knee Injuries | 1 | 2004 | 490 | 0.040 |
Why?
|
Guidelines as Topic | 2 | 2012 | 1405 | 0.040 |
Why?
|
Exfoliation Syndrome | 1 | 2000 | 110 | 0.040 |
Why?
|
Thrombocytopenia | 1 | 2007 | 1178 | 0.040 |
Why?
|
Infusions, Intravenous | 1 | 2003 | 2274 | 0.040 |
Why?
|
Cholestyramine Resin | 1 | 1998 | 24 | 0.040 |
Why?
|
Home Care Services | 1 | 2005 | 606 | 0.040 |
Why?
|
Multiple Myeloma | 1 | 2016 | 5181 | 0.040 |
Why?
|
Cardiotonic Agents | 1 | 2002 | 535 | 0.040 |
Why?
|
Cholesterol, HDL | 1 | 2005 | 1813 | 0.040 |
Why?
|
Patient Care Team | 1 | 2010 | 2531 | 0.040 |
Why?
|
Management Information Systems | 2 | 2007 | 50 | 0.040 |
Why?
|
Epidemiologic Studies | 1 | 2001 | 676 | 0.040 |
Why?
|
Family Practice | 1 | 2001 | 516 | 0.040 |
Why?
|
Cardiopulmonary Bypass | 1 | 2003 | 1066 | 0.040 |
Why?
|
Myocardial Revascularization | 2 | 2013 | 841 | 0.040 |
Why?
|
Interdisciplinary Communication | 1 | 2004 | 950 | 0.040 |
Why?
|
Electrocardiography | 3 | 2010 | 6442 | 0.040 |
Why?
|
Social Environment | 1 | 1983 | 1022 | 0.040 |
Why?
|
Quebec | 1 | 1997 | 134 | 0.040 |
Why?
|
Risperidone | 2 | 2012 | 383 | 0.040 |
Why?
|
Catheterization, Central Venous | 1 | 2002 | 514 | 0.040 |
Why?
|
Blood Vessel Prosthesis | 1 | 2002 | 934 | 0.040 |
Why?
|
Minnesota | 2 | 2009 | 344 | 0.040 |
Why?
|
Low Back Pain | 1 | 2006 | 956 | 0.040 |
Why?
|
Troponin I | 1 | 2001 | 619 | 0.040 |
Why?
|
Drug Resistance, Microbial | 1 | 2000 | 862 | 0.040 |
Why?
|
Piperidines | 1 | 2005 | 1602 | 0.040 |
Why?
|
Glycoproteins | 1 | 2005 | 2266 | 0.040 |
Why?
|
Population | 1 | 1997 | 142 | 0.040 |
Why?
|
Substance-Related Disorders | 4 | 2016 | 4257 | 0.040 |
Why?
|
New England | 2 | 1997 | 1022 | 0.040 |
Why?
|
Health Surveys | 3 | 2019 | 4036 | 0.040 |
Why?
|
Stress, Psychological | 2 | 1991 | 4245 | 0.040 |
Why?
|
Single-Blind Method | 2 | 2012 | 1590 | 0.040 |
Why?
|
Oxazolidinones | 1 | 2017 | 96 | 0.040 |
Why?
|
Ontario | 1 | 1997 | 383 | 0.040 |
Why?
|
Membrane Proteins | 2 | 2004 | 7882 | 0.030 |
Why?
|
Parathyroid Hormone | 1 | 2003 | 1800 | 0.030 |
Why?
|
Employment | 1 | 1983 | 1132 | 0.030 |
Why?
|
Self Medication | 1 | 1997 | 117 | 0.030 |
Why?
|
Esters | 1 | 2017 | 210 | 0.030 |
Why?
|
Colorectal Neoplasms | 2 | 2006 | 6773 | 0.030 |
Why?
|
Culture | 1 | 2000 | 633 | 0.030 |
Why?
|
Demography | 2 | 1993 | 1655 | 0.030 |
Why?
|
Postmenopause | 1 | 2005 | 2460 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 1 | 2003 | 35425 | 0.030 |
Why?
|
Sulfhydryl Compounds | 1 | 2017 | 298 | 0.030 |
Why?
|
Motor Activity | 1 | 2006 | 2715 | 0.030 |
Why?
|
Thyroid Diseases | 1 | 1999 | 379 | 0.030 |
Why?
|
Norway | 1 | 2016 | 448 | 0.030 |
Why?
|
Disease Management | 2 | 2012 | 2460 | 0.030 |
Why?
|
Mammography | 2 | 2007 | 2475 | 0.030 |
Why?
|
Michigan | 2 | 1986 | 350 | 0.030 |
Why?
|
Reagent Strips | 1 | 1995 | 39 | 0.030 |
Why?
|
World Health Organization | 1 | 2021 | 1318 | 0.030 |
Why?
|
Treatment Failure | 2 | 2017 | 2618 | 0.030 |
Why?
|
Home Infusion Therapy | 1 | 1995 | 19 | 0.030 |
Why?
|
Training Support | 1 | 2015 | 113 | 0.030 |
Why?
|
Reference Values | 1 | 2002 | 4982 | 0.030 |
Why?
|
Social Support | 3 | 2002 | 2118 | 0.030 |
Why?
|
Immunoglobulin G | 1 | 2007 | 4561 | 0.030 |
Why?
|
Carboxylic Ester Hydrolases | 1 | 1995 | 98 | 0.030 |
Why?
|
Cephalexin | 2 | 1986 | 37 | 0.030 |
Why?
|
Formularies as Topic | 2 | 2006 | 91 | 0.030 |
Why?
|
Independent Living | 1 | 2019 | 568 | 0.030 |
Why?
|
Vaccination | 1 | 2007 | 3279 | 0.030 |
Why?
|
Emergency Service, Hospital | 4 | 2015 | 7658 | 0.030 |
Why?
|
Colony Count, Microbial | 1 | 1995 | 331 | 0.030 |
Why?
|
Italy | 1 | 2016 | 832 | 0.030 |
Why?
|
Minority Health | 1 | 2015 | 87 | 0.030 |
Why?
|
Uridine Monophosphate | 1 | 2015 | 70 | 0.030 |
Why?
|
Mastectomy | 1 | 2003 | 1793 | 0.030 |
Why?
|
Models, Theoretical | 1 | 2006 | 3589 | 0.030 |
Why?
|
Orthopedic Procedures | 1 | 2004 | 1289 | 0.030 |
Why?
|
Consumer Advocacy | 1 | 1995 | 81 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2003 | 3480 | 0.030 |
Why?
|
Amides | 1 | 2017 | 459 | 0.030 |
Why?
|
HIV Seropositivity | 2 | 1991 | 971 | 0.030 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 2 | 2005 | 3047 | 0.030 |
Why?
|
Enema | 1 | 1994 | 141 | 0.030 |
Why?
|
Obesity | 3 | 2005 | 12746 | 0.030 |
Why?
|
Poverty Areas | 1 | 2015 | 275 | 0.030 |
Why?
|
Fluorenes | 1 | 2015 | 160 | 0.030 |
Why?
|
Renin | 1 | 1996 | 642 | 0.030 |
Why?
|
Mental Status Schedule | 2 | 1991 | 321 | 0.030 |
Why?
|
Monitoring, Physiologic | 1 | 2001 | 1739 | 0.030 |
Why?
|
Dyskinesia, Drug-Induced | 1 | 1994 | 163 | 0.030 |
Why?
|
Carbamates | 1 | 2015 | 196 | 0.030 |
Why?
|
New Hampshire | 3 | 1991 | 172 | 0.030 |
Why?
|
Dosage Forms | 1 | 2013 | 56 | 0.030 |
Why?
|
Valine | 1 | 2015 | 413 | 0.030 |
Why?
|
Diabetic Retinopathy | 1 | 2002 | 1210 | 0.030 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2015 | 215 | 0.030 |
Why?
|
Ribavirin | 1 | 2015 | 395 | 0.030 |
Why?
|
Visual Fields | 1 | 2000 | 1047 | 0.030 |
Why?
|
Pyrrolidines | 1 | 2015 | 342 | 0.030 |
Why?
|
Feedback | 2 | 2004 | 795 | 0.030 |
Why?
|
Enzyme Induction | 1 | 2013 | 475 | 0.030 |
Why?
|
Electronics | 1 | 2014 | 322 | 0.030 |
Why?
|
Self Efficacy | 2 | 2008 | 615 | 0.030 |
Why?
|
Mass Media | 1 | 2016 | 305 | 0.030 |
Why?
|
Efficiency | 2 | 2007 | 462 | 0.030 |
Why?
|
Fatal Outcome | 1 | 1997 | 1851 | 0.030 |
Why?
|
Therapeutic Human Experimentation | 1 | 1992 | 43 | 0.030 |
Why?
|
MEDLINE | 1 | 1992 | 125 | 0.030 |
Why?
|
Sex | 1 | 2012 | 57 | 0.030 |
Why?
|
Estrogen Replacement Therapy | 1 | 1999 | 1203 | 0.030 |
Why?
|
Bloodletting | 1 | 1992 | 23 | 0.030 |
Why?
|
Education, Nursing, Continuing | 1 | 1992 | 75 | 0.030 |
Why?
|
Cross Infection | 1 | 1981 | 1417 | 0.030 |
Why?
|
alpha-Glucosidases | 1 | 2012 | 44 | 0.030 |
Why?
|
Cognition Disorders | 2 | 2005 | 4043 | 0.030 |
Why?
|
Geriatric Psychiatry | 1 | 1992 | 70 | 0.030 |
Why?
|
Validation Studies as Topic | 1 | 2012 | 159 | 0.030 |
Why?
|
Case Management | 1 | 2014 | 286 | 0.030 |
Why?
|
Administration, Topical | 1 | 1994 | 690 | 0.030 |
Why?
|
Vitamin K | 1 | 2014 | 295 | 0.030 |
Why?
|
Pulse | 1 | 1992 | 229 | 0.030 |
Why?
|
Back Pain | 1 | 2016 | 545 | 0.030 |
Why?
|
Carrier Proteins | 1 | 2005 | 5023 | 0.030 |
Why?
|
Education, Continuing | 1 | 1992 | 112 | 0.030 |
Why?
|
Color | 1 | 2013 | 307 | 0.030 |
Why?
|
Urinalysis | 1 | 1994 | 369 | 0.030 |
Why?
|
Public-Private Sector Partnerships | 1 | 2012 | 121 | 0.030 |
Why?
|
Child Psychiatry | 1 | 2014 | 220 | 0.030 |
Why?
|
Chi-Square Distribution | 2 | 2000 | 3508 | 0.020 |
Why?
|
Immune Tolerance | 1 | 2000 | 2259 | 0.020 |
Why?
|
Models, Biological | 1 | 2008 | 9584 | 0.020 |
Why?
|
Escherichia coli Infections | 1 | 1995 | 532 | 0.020 |
Why?
|
Documentation | 2 | 2004 | 871 | 0.020 |
Why?
|
Cimetidine | 2 | 1987 | 78 | 0.020 |
Why?
|
Internationality | 1 | 2016 | 1002 | 0.020 |
Why?
|
Organizational Objectives | 2 | 2004 | 438 | 0.020 |
Why?
|
Methotrexate | 2 | 2008 | 1728 | 0.020 |
Why?
|
Nervous System Diseases | 1 | 2001 | 1622 | 0.020 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 2013 | 419 | 0.020 |
Why?
|
Mental Processes | 1 | 1992 | 249 | 0.020 |
Why?
|
Quality of Life | 5 | 2009 | 12802 | 0.020 |
Why?
|
Occupational Diseases | 1 | 1999 | 1469 | 0.020 |
Why?
|
Interferon-alpha | 1 | 2015 | 895 | 0.020 |
Why?
|
Rupture | 1 | 2012 | 433 | 0.020 |
Why?
|
Calcium Channel Blockers | 2 | 2006 | 692 | 0.020 |
Why?
|
Electronic Prescribing | 1 | 2011 | 121 | 0.020 |
Why?
|
Angioedema | 1 | 2012 | 187 | 0.020 |
Why?
|
Glucose | 1 | 2022 | 4398 | 0.020 |
Why?
|
Health Education | 4 | 1987 | 1056 | 0.020 |
Why?
|
Sexual Behavior | 4 | 1995 | 2055 | 0.020 |
Why?
|
Haloperidol | 1 | 2012 | 397 | 0.020 |
Why?
|
Blood Banks | 2 | 1990 | 111 | 0.020 |
Why?
|
Sympathomimetics | 1 | 1990 | 57 | 0.020 |
Why?
|
Professional Practice | 2 | 1990 | 326 | 0.020 |
Why?
|
Health Promotion | 1 | 2002 | 2205 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2007 | 9274 | 0.020 |
Why?
|
Drug Recalls | 1 | 2009 | 17 | 0.020 |
Why?
|
Achilles Tendon | 1 | 2012 | 157 | 0.020 |
Why?
|
Clinical Audit | 1 | 2009 | 31 | 0.020 |
Why?
|
Premedication | 1 | 1990 | 258 | 0.020 |
Why?
|
Organizational Case Studies | 1 | 2010 | 299 | 0.020 |
Why?
|
Journal Impact Factor | 1 | 2011 | 156 | 0.020 |
Why?
|
Sampling Studies | 1 | 1991 | 623 | 0.020 |
Why?
|
Carbonic Anhydrase Inhibitors | 1 | 1990 | 95 | 0.020 |
Why?
|
Bone and Bones | 1 | 2000 | 2576 | 0.020 |
Why?
|
Deinstitutionalization | 1 | 1989 | 21 | 0.020 |
Why?
|
Dexamethasone | 1 | 2016 | 1951 | 0.020 |
Why?
|
Uremia | 1 | 1990 | 200 | 0.020 |
Why?
|
Vitamin D | 1 | 2003 | 3224 | 0.020 |
Why?
|
Infection Control | 2 | 1990 | 965 | 0.020 |
Why?
|
Upper Gastrointestinal Tract | 1 | 2009 | 48 | 0.020 |
Why?
|
Intermediate Care Facilities | 1 | 1988 | 9 | 0.020 |
Why?
|
Rehabilitation | 1 | 1990 | 134 | 0.020 |
Why?
|
Urinary Tract Infections | 1 | 1995 | 788 | 0.020 |
Why?
|
Patient Care Planning | 2 | 1991 | 921 | 0.020 |
Why?
|
Imidazoles | 1 | 2015 | 1206 | 0.020 |
Why?
|
Imipramine | 1 | 2008 | 97 | 0.020 |
Why?
|
Review Literature as Topic | 1 | 2010 | 336 | 0.020 |
Why?
|
Institutionalization | 3 | 1994 | 104 | 0.020 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2009 | 257 | 0.020 |
Why?
|
Sulfinpyrazone | 1 | 2007 | 14 | 0.020 |
Why?
|
Mixed Function Oxygenases | 1 | 2009 | 272 | 0.020 |
Why?
|
Metals | 1 | 2012 | 719 | 0.020 |
Why?
|
Epidemiologic Factors | 1 | 2007 | 36 | 0.020 |
Why?
|
Cefazolin | 1 | 1988 | 96 | 0.020 |
Why?
|
Privacy | 1 | 2010 | 238 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2014 | 2887 | 0.020 |
Why?
|
Counseling | 3 | 2009 | 1523 | 0.020 |
Why?
|
Genotype | 2 | 2015 | 12952 | 0.020 |
Why?
|
Probenecid | 1 | 2007 | 76 | 0.020 |
Why?
|
Needs Assessment | 1 | 2014 | 1147 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2023 | 13035 | 0.020 |
Why?
|
Hepacivirus | 1 | 2015 | 1379 | 0.020 |
Why?
|
Control Groups | 1 | 2007 | 105 | 0.020 |
Why?
|
Financing, Personal | 2 | 2007 | 308 | 0.020 |
Why?
|
Posture | 1 | 1992 | 958 | 0.020 |
Why?
|
Medical Informatics | 1 | 2014 | 745 | 0.020 |
Why?
|
Etidronic Acid | 1 | 2007 | 64 | 0.020 |
Why?
|
Matched-Pair Analysis | 1 | 2007 | 288 | 0.020 |
Why?
|
Electronic Health Records | 2 | 2015 | 4468 | 0.020 |
Why?
|
Adrenergic Uptake Inhibitors | 1 | 2008 | 189 | 0.020 |
Why?
|
Stroke Volume | 1 | 1999 | 5006 | 0.020 |
Why?
|
Respiration Disorders | 1 | 1990 | 371 | 0.020 |
Why?
|
Occult Blood | 1 | 2007 | 176 | 0.020 |
Why?
|
Editorial Policies | 1 | 2011 | 451 | 0.020 |
Why?
|
Remote Consultation | 1 | 2009 | 238 | 0.020 |
Why?
|
Arkansas | 1 | 1986 | 52 | 0.020 |
Why?
|
National Health Programs | 1 | 2010 | 445 | 0.020 |
Why?
|
Vermont | 1 | 1986 | 85 | 0.020 |
Why?
|
Hydralazine | 1 | 1986 | 38 | 0.020 |
Why?
|
Clinical Competence | 2 | 1993 | 4687 | 0.020 |
Why?
|
Factor Analysis, Statistical | 1 | 2009 | 977 | 0.020 |
Why?
|
Allopurinol | 1 | 2007 | 191 | 0.020 |
Why?
|
Deltaretrovirus | 1 | 1986 | 170 | 0.020 |
Why?
|
District of Columbia | 1 | 1986 | 157 | 0.020 |
Why?
|
Fluorides | 1 | 1986 | 127 | 0.020 |
Why?
|
Absenteeism | 1 | 2007 | 250 | 0.020 |
Why?
|
Alendronate | 1 | 2007 | 171 | 0.020 |
Why?
|
Prosthesis Design | 1 | 2012 | 2110 | 0.020 |
Why?
|
Calcitonin | 1 | 2007 | 336 | 0.020 |
Why?
|
Professional Competence | 1 | 1989 | 447 | 0.020 |
Why?
|
Meta-Analysis as Topic | 1 | 2010 | 1342 | 0.020 |
Why?
|
Databases, Bibliographic | 1 | 2005 | 128 | 0.020 |
Why?
|
Databases as Topic | 1 | 2007 | 475 | 0.020 |
Why?
|
Water Supply | 1 | 1986 | 214 | 0.020 |
Why?
|
Program Evaluation | 2 | 2004 | 2488 | 0.020 |
Why?
|
Hospitals, Psychiatric | 1 | 2006 | 332 | 0.020 |
Why?
|
Hospital Costs | 2 | 2006 | 985 | 0.020 |
Why?
|
Natural Language Processing | 1 | 2013 | 1041 | 0.020 |
Why?
|
Bacterial Vaccines | 1 | 2007 | 403 | 0.020 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2007 | 595 | 0.020 |
Why?
|
Quinolones | 1 | 2007 | 367 | 0.020 |
Why?
|
New York City | 3 | 1993 | 710 | 0.020 |
Why?
|
Densitometry | 1 | 2004 | 156 | 0.020 |
Why?
|
Occupations | 1 | 2006 | 517 | 0.020 |
Why?
|
Bacteria | 1 | 1995 | 2115 | 0.020 |
Why?
|
Hospital Records | 1 | 2004 | 95 | 0.020 |
Why?
|
Neuropsychological Tests | 2 | 1994 | 6994 | 0.010 |
Why?
|
Safety | 1 | 2009 | 1186 | 0.010 |
Why?
|
United States Department of Veterans Affairs | 1 | 2008 | 875 | 0.010 |
Why?
|
Population Dynamics | 1 | 1986 | 302 | 0.010 |
Why?
|
Osteoporosis, Postmenopausal | 1 | 2007 | 386 | 0.010 |
Why?
|
Creatine Kinase, MB Form | 1 | 2004 | 214 | 0.010 |
Why?
|
Papaverine | 1 | 1983 | 46 | 0.010 |
Why?
|
Migraine Disorders | 1 | 2016 | 1620 | 0.010 |
Why?
|
Plasma | 1 | 2007 | 575 | 0.010 |
Why?
|
Helplessness, Learned | 1 | 1983 | 28 | 0.010 |
Why?
|
Group Practice | 1 | 2004 | 149 | 0.010 |
Why?
|
Pilot Projects | 3 | 2012 | 8319 | 0.010 |
Why?
|
Patient Care Management | 1 | 2006 | 306 | 0.010 |
Why?
|
Unnecessary Procedures | 1 | 2007 | 432 | 0.010 |
Why?
|
Substance Abuse, Intravenous | 3 | 1993 | 525 | 0.010 |
Why?
|
Helping Behavior | 1 | 1982 | 21 | 0.010 |
Why?
|
Perception | 1 | 2009 | 1198 | 0.010 |
Why?
|
Creatine Kinase | 1 | 2004 | 694 | 0.010 |
Why?
|
Geriatric Nursing | 1 | 1982 | 39 | 0.010 |
Why?
|
Angina Pectoris | 1 | 1986 | 977 | 0.010 |
Why?
|
Fever | 1 | 1989 | 1616 | 0.010 |
Why?
|
Education, Pharmacy, Continuing | 1 | 2001 | 3 | 0.010 |
Why?
|
Comprehension | 1 | 2007 | 610 | 0.010 |
Why?
|
Moral Obligations | 1 | 1982 | 96 | 0.010 |
Why?
|
Patient Identification Systems | 1 | 2001 | 79 | 0.010 |
Why?
|
Least-Squares Analysis | 2 | 1993 | 379 | 0.010 |
Why?
|
Medicine | 1 | 2010 | 946 | 0.010 |
Why?
|
Monte Carlo Method | 1 | 2006 | 1254 | 0.010 |
Why?
|
Peer Review, Health Care | 1 | 2001 | 75 | 0.010 |
Why?
|
Reference Standards | 1 | 2004 | 1025 | 0.010 |
Why?
|
Troponin | 1 | 2004 | 524 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 1995 | 12961 | 0.010 |
Why?
|
Computers | 1 | 1982 | 612 | 0.010 |
Why?
|
Computer Security | 1 | 2001 | 262 | 0.010 |
Why?
|
Hemodynamics | 1 | 1990 | 4196 | 0.010 |
Why?
|
Life Style | 2 | 2007 | 3835 | 0.010 |
Why?
|
Eligibility Determination | 1 | 2003 | 403 | 0.010 |
Why?
|
General Surgery | 1 | 1990 | 1636 | 0.010 |
Why?
|
Urticaria | 1 | 2000 | 150 | 0.010 |
Why?
|
Mood Disorders | 1 | 2005 | 1106 | 0.010 |
Why?
|
Rheumatology | 1 | 2005 | 576 | 0.010 |
Why?
|
Kinetics | 1 | 1986 | 6476 | 0.010 |
Why?
|
Heart Rate | 1 | 2010 | 4092 | 0.010 |
Why?
|
Health Services | 1 | 2004 | 758 | 0.010 |
Why?
|
Vasodilator Agents | 1 | 1983 | 976 | 0.010 |
Why?
|
Preventive Medicine | 1 | 2000 | 264 | 0.010 |
Why?
|
Personal Satisfaction | 1 | 1983 | 643 | 0.010 |
Why?
|
Disease Progression | 1 | 2015 | 13286 | 0.010 |
Why?
|
Physical Examination | 1 | 2004 | 1237 | 0.010 |
Why?
|
Peer Group | 1 | 1982 | 635 | 0.010 |
Why?
|
ROC Curve | 1 | 2005 | 3528 | 0.010 |
Why?
|
Piperazines | 1 | 2007 | 2488 | 0.010 |
Why?
|
Hospital Mortality | 1 | 2011 | 5316 | 0.010 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 1986 | 2232 | 0.010 |
Why?
|
Genetic Testing | 1 | 2009 | 3444 | 0.010 |
Why?
|
Body Weight | 1 | 1987 | 4671 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2007 | 6539 | 0.010 |
Why?
|
Exanthema | 1 | 2000 | 501 | 0.010 |
Why?
|
Models, Psychological | 2 | 1993 | 811 | 0.010 |
Why?
|
Defecation | 1 | 1997 | 188 | 0.010 |
Why?
|
Poverty | 1 | 2007 | 2660 | 0.010 |
Why?
|
HIV-1 | 1 | 1993 | 6939 | 0.010 |
Why?
|
Recurrence | 1 | 2007 | 8340 | 0.010 |
Why?
|
Consensus | 1 | 2004 | 2960 | 0.010 |
Why?
|
Myocardial Ischemia | 1 | 2006 | 2148 | 0.010 |
Why?
|
Benchmarking | 1 | 2001 | 1042 | 0.010 |
Why?
|
Consciousness | 1 | 2000 | 572 | 0.010 |
Why?
|
Radiography | 1 | 2006 | 7023 | 0.010 |
Why?
|
Antibodies, Viral | 1 | 1986 | 3177 | 0.010 |
Why?
|
Protein Binding | 1 | 1986 | 9384 | 0.010 |
Why?
|
Critical Care | 1 | 2007 | 2647 | 0.010 |
Why?
|
Hospital Bed Capacity, 300 to 499 | 1 | 1993 | 60 | 0.010 |
Why?
|
Osteoarthritis, Knee | 1 | 2004 | 1222 | 0.010 |
Why?
|
Tobramycin | 1 | 1993 | 69 | 0.010 |
Why?
|
Body Mass Index | 2 | 2005 | 12721 | 0.010 |
Why?
|
Forms and Records Control | 1 | 1993 | 160 | 0.010 |
Why?
|
Prothrombin Time | 1 | 1992 | 119 | 0.010 |
Why?
|
Cerebrovascular Circulation | 1 | 1982 | 2732 | 0.010 |
Why?
|
Microcomputers | 1 | 1992 | 147 | 0.010 |
Why?
|
Swine | 1 | 2002 | 5918 | 0.010 |
Why?
|
Marital Status | 1 | 1993 | 437 | 0.010 |
Why?
|
Hospitals, Community | 1 | 1993 | 347 | 0.010 |
Why?
|
Cefoxitin | 1 | 1990 | 36 | 0.010 |
Why?
|
Liver | 1 | 1986 | 7475 | 0.010 |
Why?
|
Psychological Tests | 1 | 1993 | 651 | 0.010 |
Why?
|
Blood Urea Nitrogen | 1 | 1990 | 191 | 0.010 |
Why?
|
Homosexuality | 1 | 1991 | 262 | 0.010 |
Why?
|
Nurse-Patient Relations | 1 | 1990 | 101 | 0.010 |
Why?
|
Autoimmune Diseases | 1 | 2002 | 2134 | 0.010 |
Why?
|
State Health Plans | 1 | 1991 | 216 | 0.010 |
Why?
|
Electrolytes | 1 | 1990 | 282 | 0.010 |
Why?
|
Systole | 1 | 1992 | 958 | 0.010 |
Why?
|
Diastole | 1 | 1992 | 791 | 0.010 |
Why?
|
Adaptation, Psychological | 2 | 1993 | 2575 | 0.010 |
Why?
|
Behavior Control | 1 | 1988 | 45 | 0.010 |
Why?
|
Behavioral Research | 1 | 1988 | 54 | 0.010 |
Why?
|
Mentally Ill Persons | 1 | 1988 | 126 | 0.000 |
Why?
|
Pain | 1 | 2003 | 4988 | 0.000 |
Why?
|
Flurazepam | 1 | 1987 | 8 | 0.000 |
Why?
|
Marriage | 1 | 1988 | 339 | 0.000 |
Why?
|
Blood Specimen Collection | 1 | 1987 | 246 | 0.000 |
Why?
|
Brain | 1 | 1990 | 26388 | 0.000 |
Why?
|
Behavior | 1 | 1986 | 561 | 0.000 |
Why?
|
Alcohol Drinking | 1 | 1994 | 3966 | 0.000 |
Why?
|
Surgical Procedures, Operative | 1 | 1993 | 1877 | 0.000 |
Why?
|
HIV Antibodies | 1 | 1986 | 1322 | 0.000 |
Why?
|
Exercise | 1 | 1994 | 5615 | 0.000 |
Why?
|
Fear | 1 | 1986 | 1440 | 0.000 |
Why?
|
Opium | 1 | 1973 | 29 | 0.000 |
Why?
|
Social Problems | 1 | 1973 | 112 | 0.000 |
Why?
|
Heroin Dependence | 1 | 1973 | 175 | 0.000 |
Why?
|
Animals | 1 | 2002 | 168768 | 0.000 |
Why?
|
Cannabis | 1 | 1973 | 440 | 0.000 |
Why?
|
Alcoholism | 1 | 1973 | 1906 | 0.000 |
Why?
|
Societies, Medical | 1 | 1973 | 3743 | 0.000 |
Why?
|